GeneTether Therapeutics Inc. (CSE: GTTX)
Canada
· Delayed Price · Currency is CAD
0.0800
0.00 (0.00%)
Dec 20, 2024, 4:00 PM EST
GeneTether Therapeutics Statistics
Total Valuation
GeneTether Therapeutics has a market cap or net worth of CAD 3.10 million. The enterprise value is 1.79 million.
Market Cap | 3.10M |
Enterprise Value | 1.79M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
Earnings Date | Mar 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GeneTether Therapeutics has 38.74 million shares outstanding. The number of shares has decreased by -10.68% in one year.
Current Share Class | n/a |
Shares Outstanding | 38.74M |
Shares Change (YoY) | -10.68% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 77.51% |
Owned by Institutions (%) | n/a |
Float | 8.71M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 2.33 |
P/TBV Ratio | 2.33 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -1.91 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 34.52
Current Ratio | 34.52 |
Quick Ratio | 32.83 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -57.85% and return on invested capital (ROIC) is -38.92%.
Return on Equity (ROE) | -57.85% |
Return on Assets (ROA) | -37.98% |
Return on Capital (ROIC) | -38.92% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +300.00% in the last 52 weeks. The beta is 2.07, so GeneTether Therapeutics's price volatility has been higher than the market average.
Beta (5Y) | 2.07 |
52-Week Price Change | +300.00% |
50-Day Moving Average | 0.05 |
200-Day Moving Average | 0.04 |
Relative Strength Index (RSI) | 59.25 |
Average Volume (20 Days) | 2,387 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -1.01M |
Pretax Income | -941,559 |
Net Income | -941,559 |
EBITDA | n/a |
EBIT | -1.01M |
Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Cash & Cash Equivalents | 1.31M |
Total Debt | n/a |
Net Cash | 1.31M |
Net Cash Per Share | 0.03 |
Equity (Book Value) | 1.33M |
Book Value Per Share | 0.03 |
Working Capital | 1.33M |
Cash Flow
Operating Cash Flow | -531,165 |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GeneTether Therapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 10.68% |
Shareholder Yield | 10.68% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |